Physician

Henry Q Xiong, M.D.

According to 2025 Medicare claims, Henry Xiong, M.D. (NPI: 1518910561) practices medical oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Tarrant, TX. This provider's primary affiliated billing organization is ONCOLOGY-HEMATOLOGY CONSULTANTS PA (NPI: 1629021159; TIN: 752512142) and primary practice location at 76104-4611. Xiong is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Xiong's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 331 traditional Medicare patients, billed 104,428 HCPCS/CPT codes, and received $1,949,047 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 834 prescription claims across 129 beneficiaries totaling $2,351,486 in drug costs, led by Lenvima (Lenvatinib Mesylate). DME data shows 98 claims. Open Payments data shows 26 records totaling $50,213. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $1,143,383 to $2,351,486. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $6,228 to $1,064.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	614	197,542	$1,847,092
2016	562	143,859	$1,848,751
2017	582	174,527	$2,522,294
2018	414	141,672	$2,132,639
2019	444	156,357	$2,182,248
2020	436	145,339	$2,185,961
2021	425	119,298	$1,832,509
2022	350	88,486	$1,634,569
2023	391	137,639	$1,863,572
2024	331	104,428	$1,949,047

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	186	1,468	$1,143,383
2016	198	1,586	$992,036
2017	191	1,556	$1,515,898
2018	167	1,326	$1,518,956
2019	150	1,179	$1,688,553
2020	147	1,207	$1,691,077
2021	119	813	$1,521,903
2022	129	927	$1,840,790
2023	115	806	$2,343,383
2024	129	834	$2,351,486

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	140	$43,198
2016	N/R	78	$27,385
2017	25	62	$19,932
2018	N/R	62	$11,235
2019	N/R	44	$5,528
2020	N/R	N/R	N/R
2021	N/R	43	$3,147
2022	N/R	64	$2,376
2023	N/R	115	$26,529
2024	N/R	98	$3,111

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	93	386	$137
96413	Administration of chemotherapy into vein, 1 hour or less	51	286	$100
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	67	179	$92
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	101	179	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	79	119	$69

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenvima	Lenvatinib Mesylate	28	840	$682,701
Revlimid	Lenalidomide	12	308	$190,383
Abiraterone Acetate	Abiraterone Acetate	20	600	$21,640
Eliquis	Apixaban	17	930	$17,529
Xarelto	Rivaroxaban	12	720	$12,899

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	37	$1,828
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	12	$543
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	23	$414
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	26	$326

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	21	$1,624	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$48,589	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Henry Q. Xiong, M.D.?

Tedicare shows public-source Medicare data for Henry Q. Xiong, M.D. (NPI 1518910561), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Henry Q. Xiong, M.D. have ACO affiliation data?

Henry Q. Xiong, M.D. is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Henry Q. Xiong, M.D.?

Henry Q. Xiong, M.D. is linked to ONCOLOGY-HEMATOLOGY CONSULTANTS PA (billing NPI 1629021159) in the available physician profile data.

Does Henry Q. Xiong, M.D. have Open Payments data?

Henry Q. Xiong, M.D. has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.